Background: Camel production in Saudi Arabia is severely affected by various diseases and by inadequate veterinary services. Ticks and tick-borne pathogens (TBPs) affect the health and wellbeing of camels consequently diminishing their productivity and performances. In addition, camels may act as hosts for TBPs (e.g. Anaplasma phagocytophilum) causing diseases in humans. The current study aimed to determine the prevalence of ixodid ticks and molecularly investigate the associated pathogens in camels from Saudi Arabia. Methods: Blood and tick samples were collected from camels (n = 170) in Riyad Province of Saudi Arabia. Ticks were morphologically identified, and blood of camels were molecularly screened for apicomplexan (i.e. Babesia spp., Theileria spp., Hepatozoon spp.) and rickettsial parasites (i.e. Ehrlichia spp. and Anaplasma spp.). Results: Of the 170 camels examined, 116 (68.2%; 95% CI: 60.9–75.1%) were infested by ticks with a mean intensity of 2.53 (95% CI: 2.4–2.6). In total of 296 ticks collected, Hyalomma dromedarii was the most prevalent (76.4%), followed by Hyalomma impeltatum (23.3%) and Hyalomma excavatum (0.3%). Of the tested animals, 13 (7.6%; 95% CI: 4.3–12.8%) scored positive to at least one TBP, with Anaplasma platys (5.3%; 95% CI: 2.7–9.9%) being the most prevalent species, followed by Anaplasma phagocytophilum, Anaplasma sp., Ehrlichia canis and Hepatozoon canis (0.6% each; 95% CI: 0.04–3.4%). None of the camels were found to be co-infected with more than one pathogen. All samples tested negative for Babesia spp. and Theileria spp. Conclusions: The present study reveals the occurrence of different tick species and TBPs in camels from Saudi Arabia. Importantly, these camels may carry A. phagocytophilum and A. platys, representing a potential risk to humans.

Background: Dogs play an important role as reservoirs of many zoonotic vector-borne pathogens worldwide, yet reports of canine vector-borne diseases (CVBDs) in Egypt are scarce. Methods: Serum samples were collected from pet dogs (n = 500) of the three most common breeds (German Shepherd, Rottweiler and Pit Bull) in five Governates of Cairo (n = 230), Giza (n = 110), Al-Qalyubia (n = 60), Al-Gharbia (n = 60) and Kafr El-Sheikh (n = 40) with a hot desert climate. The presence of antibodies to Anaplasma spp. (A. phagocytophilum, A. platys), Ehrlichia spp. (E. canis, E. chaffeensis, E. ewingii), Borrelia burgdorferi (s.l.) and Dirofilaria immitis were assessed using IDEXX SNAP^® 4Dx^® ELISA tests. For each pathogen, risk factors (i.e. geographical area, keeping condition, sex, age, breed, tick infestation, weekly sanitation of dog enclosures and application of ectoparasiticides) were evaluated by logistic regression approach. Results: In total, 18.2% (n = 91, 95% CI 15.1–21.8) of dogs scored seropositive for at least one pathogen, the most frequent being Ehrlichia spp. (n = 56; 11.2%; 95% CI 8.7–14.3) followed by Anaplasma spp. (n = 33; 6.6%, 95% CI 4.7–9.1), Borrelia burgdorferi (s.l.) (n = 9; 1.8%, 95% CI 0.9–3.4) and D. immitis (n = 7; 1.4%, 95% CI 0.9–2.9). In the tested population, 15.4% (95% CI 12.5–18.8) of dogs were exposed to a single pathogen while 2.4 (95% CI 1.4–4.2) and 0.4% (95% CI 0.1–1.4) were simultaneously exposed to two or three pathogens, respectively. Major risk factors associated with VBDs were living outdoors (Anaplasma spp., P = 0.0001; Ehrlichia spp., P = 0.0001), female sex (Ehrlichia spp., P = 0.005), German Shepherd breed (Anaplasma spp., P = 0.04; Ehrlichia spp., P = 0.03), tick infestation (Anaplasma spp., P = 0.0001; Ehrlichia spp., P = 0.0001; B. burgdorferi (s.l.), P = 0.003; D. immitis, P = 0.02), irregular sanitation (Anaplasma spp., P = 0.0001; Ehrlichia spp., P = 0.0001; B. burgdorferi (s.l.), P = 0.002; D. immitis, P = 0.01) and not using ectoparasiticides (Anaplasma spp., P = 0.0001; Ehrlichia spp., P = 0.0001; B. burgdorferi (s.l.), P = 0.007). Conclusion: To our knowledge, this is the first large-scale seroepidemiological study of CVBDs in Egypt. Considering that all of the detected pathogens are potentially zoonotic, effective ectoparasite control strategies, regular examination of pet dogs and successful chemoprophylaxis are advocated. Graphical

Background: In recent years, the focus on nanotechnological methods in medicine, especially in the treatment of microbial infections, has increased rapidly. Aim: The present study aims to evaluate in vitro and in vivo antileishmanial effects of copper nanoparticles (CuNPs) green synthesized by Capparis spinosa fruit extract alone and combined with meglumine antimoniate (MA). Methods: CuNPs were green synthesized by C. spinosa methanolic extract. The in vitro antileishmanial activity of CuNPs (10–200 µg/mL) or MA alone (10–200 µg/mL), and various concentrations of MA (10–200 μg/mL) along with 20 μg/mL of CuNPs, was assessed against the Leishmania major (MRHO/IR/75/ER) amastigote forms and, then tested on cutaneous leishmaniasis induced in male BALB/c mice by L. major. Moreover, infectivity rate, nitric oxide (NO) production, and cytotoxic effects of CuNPs on J774-A1 cells were evaluated. Results: Scanning electron microscopy showed that the particle size of CuNPs was 17 to 41 nm. The results demonstrated that CuNPs, especially combined with MA, significantly (p < 0.001) inhibited the growth rate of L. major amastigotes and triggered the production of NO (p < 0.05) in a dose-dependent manner. CuNPs also had no significant cytotoxicity in J774 cells. The mean number of parasites was significantly (p < 0.05) reduced in the infected mice treated with CuNPs, especially combined with MA in a dose-dependent response. The mean diameter of the lesions decreased by 43 and 58 mm after the treatment with concentrations of 100 and 200 mg/mL of CuNPs, respectively. Conclusion: The findings of the present study demonstrated the high potency and synergistic effect of CuNPs alone and combined with MA in inhibiting the growth of amastigote forms of L. major, as well as recovery and improving cutaneous leishmaniasis (CL) induced by L. major in BALB/c mice. Additionally, supplementary studies, especially in clinical settings, are required.

Since there is no potential, effective vaccine available, treatment is the only controlling option against hydatid cyst or cystic echinococcosis (CE). This study was designed to systematically review the in vitro, in vivo, and ex vivo effects of nanoparticles against hydatid cyst. The study was carried out based on the 06- PRISMA guideline and registered in the CAMARADES-NC3Rs Preclinical Systematic Review and Meta-analysis Facility (SyRF) database. The search was performed in five English databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar without time limitation for publications around the world about the protoscolicdal effects of all the organic and inorganic nanoparticles without date limitation in order to identify all the published articles (in vitro, in vivo, and ex vivo). The searched words and terms were: “nanoparticles”, “hydatid cyst”, “protoscoleces”, “cystic echinococcosis”, “metal nanoparticles”, “organic nanoparticles”, “inorganic nanoparticles, “in vitro”, ex vivo”, “in vivo”. Out of 925 papers, 29 papers including 15 in vitro (51.7%), 6 in vivo (20.7%), ex vivo 2 (6.9%), and 6 in vitro/in vivo (20.7%) up to 2020 met the inclusion criteria for discussion in this systematic review. The results demonstrated the most widely used nanoparticles in the studies were metal nanoparticles such as selenium, silver, gold, zinc, copper, iron nanoparticles (n = 8, 28.6%), and metal oxide nanoparticles such as zinc oxide, titanium dioxide, cerium oxide, zirconium dioxide, and silicon dioxide (n = 8, 28.6%), followed by polymeric nanoparticles such as chitosan and chitosan-based nanoparticles (n = 7, 25.0%). The results of this review showed the high efficacy of a wide range of organic and inorganic NPs against CE, indicating that nanoparticles could be considered as an alternative and complementary resource for CE treatment. The results demonstrated that the most widely used nanoparticles for hydatid cyst treatment were metal nanoparticles and metal oxide nanoparticles, followed by polymeric nanoparticles. We found that the most compatible drugs with nanoparticles were albendazole, followed by praziquantel and flubendazole, indicating a deeper understanding about the synergistic effects of nanoparticles and the present anti-parasitic drugs for treating hydatid cysts. The important point about using these nanoparticles is their toxicity; therefore, cytotoxicity as well as acute and chronic toxicities of these nanoparticles should be considered in particular. As a limitation, in the present study, although most of the studies have been performed in vitro, more studies are needed to confirm the effect of these nanoparticles as well as their exact mechanisms in the hydatid cyst treatment, especially in animal models and clinical settings.